Document Type
Article
Publication Date
7-31-2026
Identifier
DOI: 10.1007/s11306-026-02510-9; PMCID: PMC13427838
Abstract
OBJECTIVES: Patent ductus arteriosus (PDA) is one of the most common heart conditions in preterm infants, and indomethacin treatment is used for PDA closure. However, its efficacy varies among patients. This pilot study aimed to identify novel metabolic biomarkers to predict effective indomethacin response in infants with PDA.
METHODS: Preterm infants with PDA < 34 weeks gestational age were recruited and treated with indomethacin. Plasma and urine samples were collected before and 2-7 days after initial treatment. Longitudinal targeted oxylipin and untargeted metabolomics analysis were performed on plasma and urine samples.
RESULTS: Among 17 infants, 12 were responders and 5 non-responders to indomethacin treatment. Before the treatment, four plasma oxylipins: 12,13-DiHOME, 9,10-DiHOME, 15,16-DiHODE, and 9,10-DiHODE were significantly higher in responders compared to non-responders (P < 0.05). Following treatment, these oxylipins decreased in responders but remained stable in non-responders. Urinary 12,13-DiHOME showed an opposite trend, with lower baseline concentrations in the responders.
CONCLUSIONS: Pre-treatment plasma levels of four oxylipins were associated with effective PDA response to indomethacin. The balance of oxylipins and prostaglandins is important in duct patency and may predict which infants responding to indomethacin. These pilot findings contribute to the identification of potential neonatal pharmacometabolomic biomarkers and create new hypotheses that can guide future research towards personalized PDA management in preterm infants.
Journal Title
Metabolomics
Volume
22
Issue
4
MeSH Keywords
Humans; Ductus Arteriosus, Patent; Indomethacin; Biomarkers; Infant, Newborn; Infant, Premature; Oxylipins; Pilot Projects; Female; Male; Metabolomics; Treatment Outcome
PubMed ID
42538509
Keywords
Indomethacin; Oxylipins; Patent ductus arteriosus (PDA); Pharmacometabolomics; Preterm infants
Recommended Citation
Nguyen KCK, Yeung CHT, Scott A, Velenosi TJ, Lewis T. Select plasma oxylipins as potential biomarkers of effective indomethacin treatment response in preterm infants with patent ductus arteriosus. Metabolomics. 2026;22(4):136. Published 2026 Jul 31. doi:10.1007/s11306-026-02510-9
Comments
Grants and funding
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Publisher's Link: https://link.springer.com/article/10.1007/s11306-026-02510-9